High p53 protein expression was observed in 35% of patients with lower-risk del(5q) MDS treated with lenalidomide which was correlated with AML transformation, lower cytogenetic response to treatment, worse OS and presence of TP53 mutation [562]. The gene discussed is TP53; the disease is myelodysplastic syndrome.